Assessment of HDL Cholesterol Removal Capacity: Toward Clinical Application

Area of Science:

• Cardiovascular Science
• Biochemistry
• Lipid Metabolism

Background:

• High-density lipoprotein cholesterol (HDL-C) and cardiovascular disease (CVD) relationship is debated.
• Cholesterol efflux capacity (CEC) of HDL correlates with CVD incidence, but current assays have limitations.
• Existing CEC assays are time-consuming, lack standardization, and do not account for endogenous cholesterol donors.

Purpose of the Study:

• To introduce a novel, high-throughput, cell-free assay for evaluating HDL's capacity to accept cholesterol.
• To assess the clinical utility of this new assay, termed cholesterol uptake capacity (CUC), in predicting residual cardiovascular risk.

Main Methods:

• Development of a simple, cell-free assay system to measure HDL's cholesterol uptake capacity (CUC).
• Evaluation of CUC as a predictor of residual cardiovascular risk in patients with controlled low-density lipoprotein cholesterol.

Main Results:

• Cholesterol uptake capacity (CUC) was established as a novel metric for HDL function.
• CUC identified residual cardiovascular risk independently of traditional risk factors, including HDL-C levels.
• The CUC assay offers a potentially more accessible and efficient method compared to traditional CEC assays.

Conclusions:

• Cholesterol uptake capacity (CUC) is a promising new biomarker for cardiovascular risk stratification.
• The cell-free CUC assay addresses limitations of current CEC methods, offering clinical applicability.
• Further validation of reproducible HDL cholesterol removal capacity assays is crucial for real-world risk assessment.